Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q1 2023 Earnings Presentation
12 slides from Apellis Pharmaceuticals's earnings presentation, May 4, 2023
Slide 1: First Quarter 2023 Financial Results Conference Call
First Quarter 2023 Financial Results Conference Call May 4, 2023
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM TOWNSEND Chief Commercial Officer CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2 APELLIS PROPRIETARY INFORMATION / FOR APELLIS USE ONLY
Slide 3: Forward-looking statements
Forward-looking statements Statements in this presentation about future expectations, plans of the company’s clinical trials will warrant regulatory submissions and prospects, as well as any other statements regarding matters and whether systemic pegcetacoplan will receive approval from the that are
Slide 4: SYFOVRE is the first and only treatment available for geographic atrophy
SYFOVRE is the first and only treatment available for geographic atrophy 1 Increasing effects over time 2 Flexible dosing options (once every 25-60 days) Indicated for all patients with GA, with or without 3 subfoveal involvement Well-demonstrated safety profile in ~12,000 4 injections over 24 month
Slide 5: Apellis making strong progress in 2023
Apellis making strong progress in 2023 Paroxysmal Nocturnal Geographic Atrophy (GA): Hemoglobinuria (PNH): Pipeline: ✓ FDA approved on February 17 ✓ $20.4 million in 1Q 2023 U.S. ✓ Progressed late-stage clinical net product sales studies with partner Sobi ✓ Launched March 1; $18.4 in 1Q 2023 U.S. ne
Slide 6: SYFOVRE launch is off to an excellent start
SYFOVRE launch is off to an excellent start As of March 31, 2023: • Engaged with ~2,000 ECPs • Several academic institutions put SYFOVRE on formulary • >6,000 commercial SYFOVRE vials shipped to ECPs • Submitted application for permanent J-Code (expected • >3,400 samples shipped to Oct 1, 2023) ECPs
Slide 7: Demonstrated continued strong EMPAVELI performance
Demonstrated continued strong EMPAVELI performance As of March 31, 2023: >200 patients on therapy >300 HCPs with REMS certifications Q1 2023 U.S. Net Product Revenue ~98% patient compliance rate $20.4 Million 75% of C5 switches from Ultomiris 7
Slide 8: Leadership presence at ARVO 2023 underscores potential of SYFOVRE in GA
Leadership presence at ARVO 2023 underscores potential of SYFOVRE in GA Phase 3 Post Hoc Analyses of SYFOVRE for GA1 Next Steps Visual Function & Quality of Life Slowed Photoreceptor & Benefits vs Sham2 RPE Cell Loss ✓ Visual function and quality-of-life benefits ✓ 24-month analysis of OAKS (n=456)
Slide 9: Expanding potential indications for systemic pegcetacoplan
Expanding potential indications for systemic pegcetacoplan L AT E S T A G E IC-MPGN / ALS CAD H S C T- T M A PROGRAMS C3G U.S MARKET OPPORTUNITY ~5,0001 ~19,000 2 ~5,0001 ~ 4,000 3 Discontinued treatment in open- CURRENT label portion of study Phase 3 ongoing 2024: Phase 2 S TAT U S 2024: Phase 3 da
Slide 10: Consolidated First Quarter 2023 Financial Results
Consolidated First Quarter 2023 Financial Results (In USD Millions) Three Months Ended March 31, 2023 2022 EMPAVELI U.S. Net Product Sales $20.4 $12.1 SYFOVRE U.S. Net Product Sales $18.4 -- Licensing and Other Revenue $6.0 $2.3 Total Revenue $44.8 $14.4 Cost of Sales $7.8 $1.2 Expenses R&D Expenses
Slide 11: Positioning Apellis for an extraordinary 2023
Positioning Apellis for an extraordinary 2023 Retina in focus 1 2 3 4 Deliver the Prepare for Maximize Advance early first & only treatment ex-U.S. approvals the value of pipeline and Beam to patients with GA in GA collaboration in the U.S. … with compassion and commitment to patients 11
Slide 12: Q&A
Q&A
Apellis Pharmaceuticals — Q1 2023 Earnings Presentation on 6ix